Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation reports recurring developments as a commercial-stage biopharmaceutical company focused on hematologic malignancies. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Company updates commonly cover RYTELO net product revenue, U.S. commercialization, financial results and guidance, and continued development of imetelstat in JAK-inhibitor relapsed or refractory myelofibrosis and other hematologic malignancies. Geron news also includes investor conference participation, Nasdaq inducement grants, board appointments, executive leadership changes, and restructuring-related business updates.
Geron (GERN) granted inducement stock options for 821,250 shares to nine new employees, effective September 17, 2026.
The options have an exercise price of $1.32 per share, equal to the closing price of Geron’s common stock on the grant date, and a ten-year term. Vesting occurs over four years: 12.5% of each grant vests on the six-month employment anniversary, with the remaining shares vesting in equal monthly installments of whole shares over the following 42 months, subject to continued employment. The awards were approved by the Board’s Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and are governed by Geron’s 2018 Inducement Award Plan and the related stock option agreement form.
Geron (GERN) will participate in two upcoming investor conferences in New York in September 2026.
The company will host a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 8:00 a.m. ET and at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 3:30 p.m. ET. Live and archived audio webcasts will be accessible via the Investor section of Geron’s website.
Geron (Nasdaq: GERN) reported that, effective August 17, 2026, it granted stock options for an aggregate 311,250 common shares to six newly hired employees as employment inducements. The options have a $1.53 exercise price, ten-year term, and four-year vesting, and were granted under Nasdaq Listing Rule 5635(c)(4) pursuant to Geron’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) reported second quarter 2026 RYTELO® (imetelstat) net product revenue of $57.5 million, up 11% versus Q1 2026 and above $49.0 million a year ago. Total Q2 revenues were $57.5 million, with a net loss of $16.7 million, or $0.02 per share.
Total Q2 costs and operating expenses were $70.0 million, up from $61.5 million, driven primarily by non-cash inventory-related expenses, as cost of goods sold rose to $9.2 million. Geron ended Q2 2026 with $326.9 million in cash, cash equivalents, restricted cash and marketable securities.
For full-year 2026, Geron reiterated guidance for RYTELO net product revenue of $220–$240 million and total operating expenses of $230–$240 million. The company highlighted continued RYTELO demand growth, expansion of ordering accounts, real-world and clinical data presentations, and the appointment of a new Chief Business Officer.
Geron (Nasdaq: GERN) granted stock options for an aggregate 202,500 common shares to five newly hired employees, effective July 17, 2026, as employment inducements. The options carry a ten-year term, a $1.44 exercise price matching the grant-date close, and four-year, service-based vesting.
Geron (Nasdaq: GERN) announced it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time, accessible via the Investors and Media section of its website.
Geron (Nasdaq: GERN) granted a stock option to purchase 1,700,000 shares of its common stock to new Chief Business Officer Chinmaya Rath as an inducement to join the company. The option was granted on July 13, 2026 with an exercise price of $1.42 per share, equal to the closing price that day.
The option has a 10-year term and vests over four years: 12.5% after six months from employment start, and the remaining shares in equal monthly installments over the following 42 months, subject to continued service. The grant was approved by the Board’s Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and made pursuant to Geron’s 2018 Inducement Award Plan and related stock option agreement.
Geron (Nasdaq: GERN) announced the appointment of Chinmaya Rath as Chief Business Officer, effective July 13, 2026. According to Geron, Rath will help maximize the value of blood cancer therapy RYTELO globally and support the company’s ambition to build a leading hematology business.
Rath brings over 25 years of U.S. and global biopharma leadership, including senior roles at Novartis, Cellworks, GlycoMimetics, Omega Therapeutics and as Founder CEO of CelluRx. His experience spans major oncology launches, strategy, operations, and venture investing in life sciences.
Geron (Nasdaq: GERN) granted stock options as inducement awards to eight new employees, effective June 17, 2026. The options cover an aggregate 690,000 shares of common stock at an exercise price of $1.23 per share, matching the closing price on the grant date.
The options have a 10-year term and vest over four years: 12.5% on the six-month employment anniversary and the remainder in equal monthly installments over 42 months, subject to continued employment. The awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and Geron’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) announced participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Company management will join a fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, Florida.
A live and archived audio webcast will be available via the Investors & Media section of Geron’s website.